Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
The association of Helicobacter pylori infection and treatment with central serous chorioretinopathy
Author Affiliations & Notes
  • SHAO-YU SUNG
    Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung, Taiwan
    Kaohsiung Medical University, Taiwan
  • Wei-Shan Chang
    Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung, Taiwan
    Kaohsiung Medical University, Taiwan
  • Hui-Min Hsieh
    Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung, Taiwan
    Kaohsiung Medical University, Taiwan
  • Deng-Chyang Wu
    Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung, Taiwan
    Kaohsiung Medical University, Taiwan
  • Shwu-Jiuan Sheu
    Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung, Taiwan
    Kaohsiung Medical University, Taiwan
  • Footnotes
    Commercial Relationships   SHAO-YU SUNG None; Wei-Shan Chang None; Hui-Min Hsieh None; Deng-Chyang Wu None; Shwu-Jiuan Sheu None
  • Footnotes
    Support  Kaohsiung Medical University Hospital (KMUH-IIT-112-2-01)
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 5114. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      SHAO-YU SUNG, Wei-Shan Chang, Hui-Min Hsieh, Deng-Chyang Wu, Shwu-Jiuan Sheu; The association of Helicobacter pylori infection and treatment with central serous chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2024;65(7):5114.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Several studies have demonstrated a positive association between Helicobacter pylori(H. pylori) infection and Central serous chorioretinopathy (CSC). On the other hand, the effect of treatment of H. pylori infection on CSC had some inconsistence. We aimed to investigate the association of H. pylori infection and treatment with the occurrence of CSC in Taiwanese population.

Methods : The study was conducted with National Health Insurance Research Database in Taiwan. We collected patients over 18 years old with or without newly diagnosed peptic ulcer disease or H. pylori between 2009 to 2015 and followed until 2018 for the incidence of CSC. We further divided the H. pylori infection subjects into treated and non-treated group. The distributions of risk factors were analyzed with Chi-Square test for the categorical variables and independent t test for continuous variables. Cox proportional hazards model analyses were performed to determine the hazard ratios (HR) of CSC among the matched groups. P-value < 0.05 was defined as statistically significant.

Results : A total of 1,012,973 subjects in the non- H. pylori group and 1,012,973 patients in the H. pylori group were enrolled after propensity score matching. The incident rate ratio of CSC in H. pylori group compared to non- H. pylori group was 1.097 with 95% confidential interval (CI) of 1.094-1.100. According to cox proportional hazards model, the risk of CSC was also significant higher in H. pylori group compared to non- H. pylori group. The incident rate ratio of CSC in treated H. pylori group was higher compared to non-treated H. pylori group. (HR: 1.137, 95% CI:1.129-1.145). In cox propotional hazards model, the risk of CSC in non-treated H. pylori group was not significantly higher than non- H. pylori group while the risk of CSC incidence in treated H. pylori group compared to non- H. pylori group was significantly higher.

Conclusions : The results revealed that H. pylori infection increased the risk of CSC. However, of the H. pylori infection subjects, treatment of H. pylori had even higher risk to develop CSC. Our findings were in line with current studies that H. pylori infection is one of the risk factors of CSC. However, we found that treatment of H. pylori further increased the risk of CSC which was contrary to the results of most of the other research. Additional research is essential to substantiate our findings.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×